Curated news and analysis on clinical trials, drug approvals, and medical research.
Recent advances in genetic science are shifting colorectal cancer screening toward direct detection of DNA changes. In India, CRC is now the fourth most common cancer, with more than 64,000 new cases and over 38,000 deaths reported in 2022.
Soon-to-be brides and grooms in India are increasingly seeking Mounjaro and other weight-loss injections before weddings, with doctors reporting rising demand. The trend comes as India’s obesity-drug market expands, cheaper semaglutide versions enter the market, and regulators raise misuse concerns.
FDA said in early February 2026 that it is taking issue with “same active ingredient” claims in compounded drug advertising. The stance contrasts with longstanding agency frameworks for active ingredient sameness in generics and compounding.
Indonesia’s contribution to the International Stabilization Force in Gaza is set to start deploying in April, with 1,000 soldiers initially and around 8,000 by June. The force is expected to supervise ceasefire lines and border-related issues, though deployment still depends on conditions in Gaza.
Illuminate 3.0 brought global and Indian oncology experts to Mumbai for a three-day townhall on precision oncology, immunotherapy, cellular therapies and cancer vaccines. Discussions covered CAR-T cell therapy, multi-cancer early detection and access to novel drugs in India.
Alterity is preparing for a mid-2026 end-of-Phase II FDA meeting for ATH434 in Multiple System Atrophy. Phase II data showed clinically meaningful and statistically significant effects, with safety comparable to placebo.
Scientists are testing experimental cancer therapies including mRNA therapeutic vaccines, engineered EcN bacteria that deliver romidepsin in mice, and macrophage-targeted CAR T cells.
A rectal cancer study found hypofractionated radiotherapy increased ISG15+MHC-I+ neutrophils with antigen-presenting capabilities. The report linked the effect to IFN-α/NOD1 signaling and improved anti-PD-1 responses in models.
Neumora said it plans higher-dose NMRA-511 work in 2026 and pivotal studies in 2027 after additional phase 1b analyses in Alzheimer’s disease agitation. The company also scheduled its fourth-quarter and full-year 2025 financial results update for March 30, 2026.
Studies of psilocybin found lasting shifts in life values in healthy volunteers and reduced fear of death in therapeutic settings. Trials have also reported benefits in cancer patients.
Researchers used machine learning to identify an antimicrobial peptide, LR, that reduced inflammation and improved gut barrier function in mouse ulcerative colitis. The peptide also reshaped the microbiome and outperformed 5-aminosalicylic acid and ciprofloxacin in the model.
An observational study in Documenta Ophthalmologica found the MLSDT showed reliability above 0.50 in advanced retinitis pigmentosa and correlated with visual acuity, visual fields and patient-reported outcomes. The test is being used as a secondary endpoint in the phase 2b/3 RESTORE trial of MCO-010.
Trump administration cuts to U.S. science funding have raised fears of a brain drain, with thousands of grants cancelled and researchers moving abroad. Experts warned the losses could damage biomedical innovation and the economy.
A study published on February 17, 2026 validated an AI workflow that predicted colorectal cancer risk in ulcerative colitis with 99% accuracy using over 55,000 patient records. The model identified low-risk and higher-risk patients from clinical notes, colonoscopy reports, and pathology findings.
Large-cap healthcare stocks such as Johnson & Johnson and CVS Health are viewed as defensive in a slowdown, with beta values of 0.33 and 0.46. Investors can also pursue higher-risk healthcare companies such as Grail and Viking Therapeutics, whose performance depends more on clinical and product milestones.
Indian pharmaceutical leaders said the industry’s next phase of growth depends on innovation at scale, partnerships, stronger R&D and AI adoption. A market study projected the co-development partnering market in pharma, biotech and diagnostics to grow from USD 78.5 billion in 2024 to USD 165.2 billion by 2033.
Arrowhead Pharmaceuticals is in focus after first-quarter results moved from a year-ago loss to profitability and the company shifted from the S&P 600 to the S&P 400. Investors are also watching progress in its RNAi pipeline, including two Phase 3 therapies, while valuation measures show a mixed picture.
Ultragenyx began a restructuring plan that includes a 10% workforce reduction and termination of UX143 manufacturing agreements. The company also faces a class action tied to setrusumab disclosures.
Researchers developed a smart DNA drug that activates only when two cancer markers are present on a cell. In laboratory experiments, it delivered potent drugs to cancer cells while sparing nearby healthy cells.
Pfizer and Valneva said their investigational Lyme disease vaccine showed more than 70% efficacy in the Phase 3 VALOR trial with a favorable safety profile. The companies plan regulatory submissions despite the trial missing its primary statistical criterion due to fewer Lyme cases than expected.
